Array BioPharma Inc.

Robert E. Conway has agreed to serve as a director on our board upon completion of this offering. Mr. Conway is currently the chief executive officer of Array BioPharma Inc., which he joined in November 1999. Prior to joining Array BioPharma, Mr. Conway was the chief operating officer and executive vice president of the Clinical Trials Division of Hill Top Research, Inc., which he joined in 1996. Mr. Conway serves on the boards of directors of Array BioPharma and DEMCO, Inc. Mr. Conway received a B.S. in accounting from Marquette University and an M.B.A. from the University of Cincinnati, and is a Certified Public Accountant.

Douglas E. Williams, Ph.D., 50, has served as a member of our Board of Directors since April 2004. He currently serves as President of ZymoGenetics, Inc. From September 2003 to August 2004, Dr. Williams served as Seattle Genetics' Chief Scientific Officer, Executive Vice President and a member of their Board of Directors. Prior to joining Seattle Genetics, from November 2002 to August 2003, Dr. Williams was Head of Health and Strategic Development for Genesis Research & Development, a biotechnology company located in New Zealand. From July to October 2002, he served as Senior Vice President, Washington Site Leader and a member of the Executive Committee for Amgen, Inc. Dr. Williams joined Amgen in July 2002 when it acquired Immunex Corporation, where he worked for 14 years, most recently serving as Executive Vice President, Chief Technology Officer and a member of Immunex's Board of Directors. Prior to his work at Immunex, Dr. Williams served on the faculty of the Indiana University School of Medicine and the Department of Laboratory Medicine at the Roswell Park Memorial Institute. He serves on the boards of privately-held Aerovance, Inc. and of publicly traded Anadys Pharmaceuticals, Inc. and is a member of the Scientific Advisory Board of Symphony Capital. Dr. Williams holds a B.S. magna cum laude in Biological Sciences from the University of Massachusetts, Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo, Roswell Park Division.

Kevin Koch, Ph.D., 48, is a Co-Founder of Array and has served as our President, Chief Scientific Officer and a member of our Board of Directors since May 1998. Prior to forming Array, Dr. Koch was an Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams for Amgen Inc. from 1995 to 1998. From 1988 until 1995, Dr. Koch held various positions with Pfizer Central Research, including Senior Research Investigator and Project Coordinator for the Cellular Migration and Immunology Project Teams. From 1998 to 2003, Dr. Koch was an elected board member of the Inflammation Research Association. Dr. Koch received a B.S. in chemistry and biochemistry from the State University of New York at Stony Brook and a Ph.D. in synthetic organic chemistry from the University of Rochester.

David L. Snitman, Ph.D., 55, is a Co-Founder of Array and has served as our Chief Operating Officer, our Vice President of Business Development and a member of our Board of Directors since May 1998. Prior to forming Array, Dr. Snitman held various positions with Amgen Inc. since December 1981, including Associate Director, New Products and Technology and Manager of Amgen s Boulder research facility. Dr. Snitman currently serves on the Board of Directors of Barofold Inc. Dr. Snitman received a B.S. in chemistry from Northeastern University and a Ph.D. in the synthesis of natural products from the University of Colorado, and was a National Institutes of Health Postdoctoral Fellow at the Massachusetts Institute of Technology.

Dr. Josey has served as Vice President of Discovery Chemistry since September 2004. From May 1998 to August 2004, Dr. Josey was the Senior Director of Lead Generation. Prior to joining Array, Dr. Josey had been employed by Amgen Inc. since 1995 in the New Leads/Combinatorial Chemistry Group of Amgen's small molecule drug discovery program. From 1991 until 1995, Dr. Josey was a Research Investigator in the Medicinal Chemistry Department at the Glaxo Research Institute. Dr. Josey received a B.S. degree in chemistry from Colorado State University, a Ph.D. degree in organic chemistry from The University of Texas at Austin, and was a Damon Runyon-Walter Winchell Postdoctoral Fellow at the California Institute of Technology.

John is the Chairman and CEO of the Marwood Group, a healthcare investment and financial services firm. John is a graduate of the University of North Carolina at Chapel Hill. John is married and lives with his wife Tanya, their daughter, Alexandra and son John Jr. in New York.

Dr. Rizzi has served as Director of Computational Technology since February 2001. Prior to joining Array, Dr. Rizzi served as Senior Director of Business Development for Tripos Inc. from 1999 to 2001. Dr. Rizzi was Head of Chemistry and Structural Biology for Source Pharmaceuticals from 1998 to 1999 and was a Lab Head at Amgen, Boulder in charge of computational chemistry from 1995 to 1998. From 1981 to 1995 Dr. Rizzi was at Pfizer Central Research where his early career focused on medicinal chemistry in the fields of diabetes and immunology. In 1989, he joined the computational chemistry group at Pfizer. His responsibilities included support of the CNS, inflammation, immunology, and infectious disease areas. Dr. Rizzi received his B.S. degree in chemistry from Hofstra University and a Ph.D. in synthetic chemistry from the University of Rochester.

Dr. Boyd has served as Director of Medicinal Chemistry since October 2000. Prior to joining Array, Dr. Boyd was Senior Group Leader in the Pharmaceutical Products Division of Abbott Laboratories, where his research areas included drug discovery in cardiovascular, inflammatory, immunological, and metabolic diseases. Dr. Boyd received a B.A. in chemistry from the University of Oregon Honors College, and a Ph.D. in organic chemistry from the University of California, Los Angeles. He was a National Cancer Institute post-doctoral fellow at the University of Wisconsin.

Dr. Johnson, with over 30 years of experience in government and industry, has worked in all aspects of cancer drug discovery/development. This experience ranges from target validation, through screening technologies, basic research on mechanisms of drug action, assessment of efficacy in preclinical tumor models, to clinical development plans and regulatory strategies. He has put many drugs into clinical development and is credited with bringing topotecan to market. After receiving a degree in Pharmacology, Dr. Johnson worked at the National Cancer Institute, at Arthur D Little, and for 20 years at GlaxoSmithKline / SmithKline Beecham Pharmaceuticals. He now consults for many pharmaceutical companies, both large and small, provides venture capital groups with assessment of investment opportunities and serves on the Scientific Advisory Boards of five other biotechnology companies.

Dr. Francis Bullock is a Senior Advisor to PureTech Ventures. Previously, he served as the Senior Vice President, Research Operations at Schering Plough Research Institute, from 1981-1993, where he took over 30 new chemical entities into clinical development in many therapeutic areas including antibacterials, antifungals, antivirals, cardiovasculars, pain, inflammation, allergy, and cancer. His track record includes five successful registrations including Claritin and Intron (Interferon Alpha 2b) that generated cumulative peak sales of around $3.5B annually. Dr. Bullock serves on the board of directors for TSI Corporation, Genzyme Transgenics Corporation, Array Biopharma, and ARCA Discovery.

Gil J. Van Lunsen was appointed to the audit committee on March 8, 2005. Van Lunsen was a managing partner of KPMG LLP and led the firm's Tulsa, Oklahoma, office before retiring in June 2000. During his career, Van Lunsen served clients in several industries including energy. He is currently a director and audit committee chairman of Array Biopharma and Sirenza Microdevices. Additionally, Van Lunsen was a member of the ethics compliance committee of Tyson Foods, Inc. and the audit committee chairman and member of the board of directors for Hillcrest Healthcare System.

Dr. Lyssikatos has served as Director of Lead Optimization since May 2003. Before joining Array, Dr. Lyssikatos had been employed by Thios Pharmaceuticals to build and lead their medicinal chemistry and in-vitro pharmacology groups. From 2001 until 2002, Dr. Lyssikatos was employed by Array, most recently serving as Senior Group Leader for the Company's proprietary oncology and inflammation research programs. Prior to joining Array, Dr. Lyssikatos was employed for nine years by Pfizer Inc. focusing on various research areas, including PDGFR inhibitors, Ftase inhibitors, immune stimulants and antibacterials. Dr. Lyssikatos received a B.S. in chemistry from The College of William and Mary and a Ph.D. from The University of California at Berkeley.